Related content

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates

By Earnshaw S. R.   Graham C. N.   Ettinger B.   Amonkar M. M.   Lynch N. O.   Middelhoven H.  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2517-2529

Informa Healthcare

Access to resources Recommend Favorite

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

By Cramer Joyce A.   Amonkar Mayur M.   Hebborn Ansgar   Altman Roy  

Current Medical Research and Opinion, Vol. 21, Iss. 9, 2005-09 ,pp. : 1453-1460

Informa Healthcare

Access to resources Recommend Favorite

A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis

By Gold Deborah T.   Martin Bradley C.   Frytak Jennifer R.   Amonkar Mayur M.   Cosman Felicia  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 585-594

Informa Healthcare

Access to resources Recommend Favorite

Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis

By Marquis P.   Roux C.   de la Loge C.   Diaz-Curiel M.   Cormier C.   Isaia G.   Badurski J.   Wark J.   Meunier P.  

Osteoporosis International, Vol. 19, Iss. 4, 2008-04 ,pp. : 503-510

Springer Publishing Company

Access to resources Recommend Favorite

Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women

By Breuil V.  

Osteoporosis International, Vol. 23, Iss. 2, 2012-02 ,pp. : 445-455

Springer Publishing Company

Access to resources Recommend Favorite